Characterizing propagation and vortex-splitting dynamics of Bessel-Gaussian beams in short-range atmospheric conditions.

This study explores the propagation dynamics of Bessel-Gaussian (BG) beams, focusing on vortex-splitting behavior under short-range atmospheric conditions with varying disturbances. Using the split-step beam propagation method, the research reveals that greater atmospheric turbulence and longer transmission distances enhance both the average vortex splitting distance and its variance while reducing the average topological charge of the received OAM mode. Conversely, laminar conditions promote beam stability.

Deciphering the complex clonal heterogeneity of polycythemia vera and the response to interferon alpha.

Interferon alpha (IFNa) is approved for the therapy of patients (pts) with polycythemia vera (PV), a subtype of myeloproliferative neoplasms (MPN). Some pts achieve molecular responses (MR), but clonal factors sensitizing for MR remain elusive. We integrated colony formation and differentiation assays with single-cell RNA seq and genotyping in PV-derived cells vs.

The expression of repulsive guidance molecule a in the rat brain and the diffusion tensor imaging evaluation for crossed cerebellar diaschisis.

Background: Cerebral infarction is one of the most common diseases. Diffusion tensor imaging (DTI) has been used to evaluate for crossed cerebellar diaschisis (CCD) to observe the expression of repulsive guidance molecule a (RGMa), the axonal regeneration as well as the effect on neural functional recovery in the middle cerebral artery occlusion (MCAO) rat model.

Purpose: To certify the expression pattern of RGMa in cerebral infarction and the mechanism of CCD to provide a new target for clinical therapy.

Efficacy and safety of the combination of anlotinib and envafolimab in the treatment of unresectable or metastatic liposarcoma: findings from a single-center retrospective study.

Objective: To evaluate the efficacy and safety of anlotinib combined with envafolimab in the treatment of unresectable or metastatic liposarcoma.

Methods: This single-center, retrospective study enrolled 15 patients with unresectable or metastatic liposarcoma, who were treated at the Retroperitoneal Tumor Surgery Research Center of Qingdao University Affiliated Hospital between April 2022 and November 2023. The treatment regimen consisted of anlotinib combined with envafolimab.